Bionexus Gene Lab Corp (BGLC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 09-2025 | 06-2025 | 03-2025 | 12-2024 | |
| Sales | 484 | 2,544 | 2,260 | 2,137 | 2,524 |
| Cost of Goods | 488 | 2,166 | 1,892 | 1,794 | 2,215 |
| Gross Profit | -4 | 378 | 368 | 344 | 309 |
| Operating Expenses | 1,517 | 1,246 | 1,872 | 1,756 | 940 |
| Operating Income | -1,033 | -703 | -611 | -618 | -416 |
| Interest Expense | 10 | 21 | 30 | 24 | 34 |
| Other Income | 7 | 14 | 25 | 19 | 28 |
| Pre-tax Income | -1,036 | -709 | -616 | -623 | -422 |
| Income Tax | N/A | N/A | N/A | N/A | -74 |
| Net Income Continuous | -1,036 | -709 | -616 | -623 | -348 |
| Net Income | $-1,036 | $-709 | $-616 | $-623 | $-348 |
| EPS Basic Total Ops | -0.83 | -0.40 | -0.34 | -0.04 | -0.26 |
| EPS Basic Continuous Ops | -0.84 | -0.39 | -0.34 | -0.03 | -0.26 |
| EPS Diluted Total Ops | -0.83 | -0.40 | -0.34 | -0.04 | -0.26 |
| EPS Diluted Continuous Ops | -0.84 | -0.39 | -0.34 | -0.03 | -0.26 |
| EPS Diluted Before Non-Recurring Items | N/A | -0.39 | -0.34 | -0.03 | N/A |
| EBITDA(a) | $-980 | $-638 | $-540 | $-555 | $-339 |